

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/530,061
Filing Date	April 4, 2005
First Named Inventor	John SIDNEY
Art Unit	1643
Examiner Name	BRISTOL, Lynn Anne
Attorney Docket Number	2473.0330002/EKS/PAC

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If Known)			
/L.B./	US1	5,753,233	05-19-1998	Bleul <i>et al.</i>	
/L.B./	US2	5,783,567	07-21-1998	Hedley <i>et al.</i>	
/L.B./	US3	2002/0119127 A1	08-29-2002	Sette <i>et al.</i>	
	US4				
	US5				
	US6				
	US7				
	US8				
	US9				
	US10				
	US11				
	US12				
	US13				
	US14				
	US15				
	US16				
	US17				
	US18				
	US19				
	US20				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
/L.B./	FP1	WO 91/18294	11-28-1991	Medscand AB		
	FP2	WO 93/22338	11-11-1993	Rijksuniversiteit te Leiden		
	FP3	WO 99/45954	09-16-1999	Epimmune, Inc.		
	FP4	WO 97/41440	11-06-1997	Rijksuniversiteit te Leiden <i>et al.</i>		
	FP5	EP 0 593 754	04-27-1994	Rijksuniversiteit Leiden <i>et al.</i>		
	FP6	WO 01/019408	03-22-2001	Zycos Inc.		
	FP7	WO 04/011650	02-05-2004	Intercell AG		
	FP8	WO 99/45954	09-16-1999	Epimmune, Inc.		
	FP9	WO 01/41799	06-14-2001	Epimmune Inc.		

1038522_1.DOC

Examiner Signature	/Lynn Bristol/	Date Considered	04/26/2010
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Application Number	10/530,061
Filing Date	April 4, 2005
First Named Inventor	John SIDNEY
Art Unit	1643
Examiner Name	BRISTOL, Lynn Anne
Attorney Docket Number	2473.0330002/EKS/PAC

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If Known)			
	US1				
	US2				
	US3				
	US4				
	US5				
	US6				
	US7				
	US8				
	US9				
	US10				
	US11				
	US12				
	US13				
	US14				
	US15				
	US16				
	US17				
	US18				
	US19				
	US20				

[illegible]

/Lynn Bristol/

Examiner Signature		Date Considered	04/26/2010
-----------------------	--	--------------------	------------

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/530,061	
			Filing Date	April 4, 2005	
			First Named Inventor	John SIDNEY	
			Art Unit	1643	
			Examiner Name	BRISTOL, Lynn Anne	
Sheet	1	of	2	Attorney Docket Number	2473.0330002/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/L.B./	NPL1	Alexander, M., <i>et al.</i> , "Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope," <i>Am. J. Obstet. Gynecol.</i> 175:1586-1593, Mosby-Year Book (1996)	
	NPL2	Bremers, A.J.A., <i>et al.</i> , "The Use of Epstein-Barr Virus-Transformed B Lymphocyte Cell Lines in a Peptide-Reconstitution Assay: Identification of CEA-Related HLA-A*0301-Restricted Potential Cytotoxic T-Lymphocyte Epitopes," <i>J. Immunother.</i> 18:77-85, Lippincott-Raven (1995)	
	NPL3	Busch, R., <i>et al.</i> , "Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces," <i>Int. Immunol.</i> 2:443-451, Oxford University Press (1990)	
	NPL4	Feltkamp, M.C.W., <i>et al.</i> , "Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells," <i>Eur. J. Immunol.</i> 23:2242-2249, VCH Verlagsgesellschaft (1993)	
	NPL5	Kast, W.M., <i>et al.</i> , "Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins," <i>J. Immunol.</i> 152:3904-3912, American Association of Immunologists (1994)	
	NPL6	Melief, C.J.M., and Kast, W.M., "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication in General," <i>Cancer Surv.</i> 13:81-99, Cold Spring Harbor Press (1992)	
	NPL7	Rammensee, H-G., <i>et al.</i> , "MHC ligands and peptide motifs: first listing," <i>Immunogen.</i> 41:178-228, Springer-Verlag (1995)	
	NPL8	Ressing, M.E., <i>et al.</i> , "Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A*0201-Binding Peptides," <i>J. Immunol.</i> 154:5934-5943, American Association of Immunologists (1995)	
	NPL9	Schulz, M., <i>et al.</i> , "Peptide-induced antiviral protection by cytotoxic T cells," <i>Proc. Natl. Acad. Sci. USA</i> 88:991-993, National Academy of Sciences (1991)	
	NPL10	Sidney, J., <i>et al.</i> , "Specificity and Degeneracy in Peptide Binding to HLA-B7-Like Class I Molecules," <i>J. Immunol.</i> 157:3480-3490, American Association of Immunologists (1996)	

Examiner Signature	/Lynn Bristol/	Date Considered	04/26/2010
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/530,061
				Filing Date	April 4, 2005
				First Named Inventor	John SIDNEY
				Art Unit	1643
				Examiner Name	BRISTOL, Lynn Anne
Sheet	2	of	2	Attorney Docket Number	2473.0330002/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
/L.B./	NPL11	Toes, R.E.M., <i>et al.</i> , "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion," <i>Proc. Natl. Acad. Sci. USA</i> 94:14660-14665, National Academy of Sciences (1997)	
/L.B./	NPL12	Geisbell, J., <i>et al.</i> , "Detection and characterization of human papillomavirus type 45 DNA in the cervical carcinoma cell line MS751," <i>Journal of General Virology GB</i> 78:655-658, Angewandte Tumorstudiologie (1997)	
/L.B./	NPL13	Malik, A., <i>et al.</i> , "Identification of a Nonameric H-2K ^k -Restricted CD8 ⁺ Cytotoxic T Lymphocyte Epitope on the <i>Plasmodium falciparum</i> Circumsporozoite Protein," <i>Infection and Immunity USA</i> 63: 1955-1959, American Society for Microbiology (1995)	
	NPL14		
	NPL15		
	NPL16		
	NPL17		
	NPL18		
	NPL19		
	NPL20		

1038524_1.DOC

Examiner Signature	/Lynn Bristol/	Date Considered	04/26/2010
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.